

Cont B1
technique (Kozbor, D. and Roder, J.C. (1983) The production of monoclonal antibodies from human lymphocytes, Immunology Today, vol. 4, pp. 72-79) and the EBV-hybridoma technique (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

IN THE CLAIMS:

Please replace the amended claims as follows:

- B2
1. (AMENDED) An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
 - a) a nucleotide sequence encoding the IGS1 polypeptide according to SEQ ID NO: 2;
 - b) a nucleotide sequence of the DNA insert contained in the deposit no. CBS 102049 wherein the nucleotide sequence is SEQ ID NO: 1;
 - c) a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence of (a) or (b); and
 - d) a nucleotide sequence that is complementary to the nucleotide sequence of (a) or (b) or (c).
 2. (AMENDED) The polynucleotide of claim 1, wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:1, and wherein the nucleotide sequence encodes an IGS1 polypeptide of SEQ ID NO:2.
 3. (AMENDED) The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to that of SEQ ID NO:1.
 6. (AMENDED) An expression system comprising a DNA or RNA molecule, wherein said expression system produces an IGS1 polypeptide comprising an amino

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com